Results 131 to 140 of about 23,420 (253)

Tumors and tumor-like lesions of the gall bladder—A review

Indian Journal of Pathology and Microbiology
Gall bladder carcinoma (GBC) remains a formidable diagnostic and therapeutic challenge, characterized by its often-incidental discovery and diverse spectrum of lesions, spanning from benign mimickers to malignant neoplasms.
Nuzhat Husain, Saumya Shukla, Pallavi Srivastava   +2 more
doaj   +1 more source

The Patient, the Provider, and the TikTok Creator: Qualitative Analysis of the Content and Quality of Videos on Prenatal Genetic Screening

Journal of Midwifery &Women's Health, EarlyView.
Introduction Although providers may view the use of the noninvasive prenatal testing (NIPT) screen as an opportunity for patients to learn more about potential chromosomal variants of a fetus, research suggests that patients may view the genetic screening test primarily as an opportunity to learn about their fetus's sex chromosomes and may not ...
Erin P. Johnson, Naomi O. Riches, Stephanie Arceneaux, Emma Murdock, Caitlin Quade, Susanna R. Cohen, Robin E. Jensen   +6 more
wiley   +1 more source

Blood‐Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations

International Journal of Cancer, Volume 159, Issue 4, Page 1028-1041, 15 August 2026.
Early detection of colorectal cancer via population‐based screening programs can reduce incidence and mortality, but current screening approaches are limited. This systematic review evaluated the screening potential of blood‐based circulating tumor DNA assays in asymptomatic screening populations.
Caroline Ledertoug Kahn, Maria Wissing Rasmussen, Jakob Kleif, Inge Søkilde Pedersen, Christina Therkildsen   +4 more
wiley   +1 more source

Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma

International Journal of Cancer, Volume 159, Issue 4, Page 1068-1078, 15 August 2026.
Commercial circulating tumor DNA (ctDNA) liquid biopsy tests are increasingly used for disease monitoring and surveillance in melanoma. However, data regarding the possible correlations between ctDNA and baseline clinical and radiometabolic parameters such as metastatic locations, tumor volume, and tumor glycolysis in patients with BRAF‐mutated ...
Ronen Stoff, Gokce Belge Bilgin, Yalda Nikanpour, Geoffrey B. Johnson, Benjamin R. Kipp, David M. Zahrieh, Katherine B. Geiersbach, Matthew S. Block, Svetomir N. Markovic   +8 more
wiley   +1 more source

dd-cfDNA Significantly Improves Rejection Yield in Kidney Transplant Biopsies

Donor-derived cell-free DNA (dd-cfDNA) is a biomarker that enables the early detection of immune-mediated graft injury. This study evaluated the clinical utility of dd-cfDNA in predicting the presence of biopsy-proven rejection (BPAR).
Akalin, Enver, Anand, Sanjiv, Mandelbrot, Didier, Huang, Edmund, Rogers, Jeffrey, Wojciechowski, David, Taber, David J, Bromberg, Jonathan S, Cooper, Matthew, Woodward, Robert N, Kumar, Dhiren, Costa, Nadiesda, Weir, Matthew R, Chuang, Peale, Klein, Jeffrey A, Glehn-Ponsirenas, Renata, Shen, Ling, Brennan, Daniel C, Kothari, Ashish S, Bu, Lihong   +19 more
core   +1 more source

Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

American Journal of Hematology, Volume 101, Issue 8, Page 1818-1827, August 2026.
ABSTRACT CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies.
Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen‐kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J. Frank   +12 more
wiley   +1 more source

Factors affecting cfDNA test failure (multivariate analysis).

Factors affecting cfDNA test failure (multivariate analysis).
Tomas Sladecek (18121408), Gabriel Minarik (2512540), Tomas Szemes (4780383), Martina Sekelska (18121411), Andrej Gnip (9306193), Natalia Forgacova (15253813), Jaroslav Budis (837494), Michaela Hyblova (837491), Juraj Gazdarica (4780389), Marcel Kucharik (9306190)   +9 more
core   +1 more source

Microfluidic nanochips for rapid exosome isolation and multiplex biomarker profiling from a single blood drop: Toward sample‐to‐answer liquid biopsy

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
A microfluidic nanodevice that analyses a single volume droplet of whole blood (10–50 microlitres (µL)) forms a fast and fully integrated exosome‐derived liquid biopsy. The closed system architecture involves plasma separation on chip, exosome enrichment by immunoaffinity and various size based, electrokinetic, acoustofluidic or hybridized strategies ...
Daniel Ejim Uti, Esther Ugo Alum, Josephine E. Egbung, Waheeb Sami Aggad, Hailah M. Almohaimeed, Zuhair M. Mohammedsaleh, Manpreet Kaur, Kranti Kiran Reddy Ealla   +7 more
wiley   +1 more source

Quantification of circulating cell-free DNA (cfDNA) in urine using a newborn piglet model of asphyxia

, 2019
Cell free DNA (cfDNA) in plasma has been described as a potential diagnostic indicator for a variety of clinical conditions, including neonatal hypoxia.
Polona Rajar (5496146), Ola Didrik Saugstad (8207547), Rajar, Polona, Monica Åsegg-Atneosen (6008963), Ola Didrik Saugstad, Lars Oliver Baumbusch (8207550), Baumbusch, Lars Oliver, Solberg, Rønnaug, Rønnaug Solberg, Saugstad, Ola Didrik, Rønnaug Solberg (252034), Atneosen-Åsegg, Monica, Monica Åsegg-Atneosen, Lars Oliver Baumbusch, Polona Rajar   +14 more
core   +1 more source

Tumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation

International Journal of Cancer, Volume 159, Issue 2, Page 302-319, 15 July 2026.
Abstract Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome ...
Whi‐An Kwon, Min‐Kyung Lee, Eunyong Ahn, Heeyeon Kim, Yong Sang Song, Taejin Ahn   +5 more
wiley   +1 more source